In a rigorous crossover trial, oral CBD doses as low as 20 mg altered plasma levels of the body's natural cannabinoid anandamide—and the effects differed between men and women.
CBD researchers, pharmacologists studying the endocannabinoid system, and anyone interested in sex differences in cannabis response.
What the researchers found
The endocannabinoid system doesn't just respond to cannabis—it produces its own cannabinoid-like molecules. This triple-blind, placebo-controlled crossover trial asked whether commercially available CBD doses affect these endogenous molecules.
Seventy healthy occasional cannabis users each received five conditions in randomized order: placebo and four CBD doses (20, 50, 100, and 200 mg). Blood was sampled at baseline and five timepoints after dosing to track three endogenous lipid signals: anandamide (AEA), N-palmitoylethanolamine (PEA), and N-oleoylethanolamine (OEA).
CBD did alter plasma levels of these signaling lipids, meaning even consumer-level doses have measurable effects on the endocannabinoid system. But the most striking finding was sex-specific: men and women showed different dose-response patterns. The statistical models included sex as a variable and found significant sex interactions.
This matters because anandamide is involved in mood regulation, pain perception, appetite, and immune function. If CBD modifies anandamide levels differently in men versus women, it could explain why men and women sometimes respond differently to CBD products—and why clinical trials that don't analyze by sex might miss important effects.
Why it matters
Most people taking CBD products have no idea whether or how it's affecting their endocannabinoid system. This study shows that even the lowest commercially available dose (20 mg) has measurable effects on endocannabinoid signaling—and that biological sex modifies those effects. For a product marketed as one-size-fits-all, the sex difference finding suggests dosing may need to be personalized.
The numbers in context
N = 70. 5 conditions: placebo + 20, 50, 100, 200 mg CBD. 6 blood sampling timepoints per session. Plasma AEA, PEA, and OEA measured by LC-MS. Significant sex differences in dose-response. Even 20 mg CBD altered endocannabinoid levels.
How the study worked
Triple-blind, placebo-controlled, randomized crossover trial. 70 healthy occasional cannabis users received 10 sequences of 4 oral CBD doses (20, 50, 100, 200 mg) and placebo. Blood sampled at baseline and 5 post-dose timepoints. Plasma AEA, PEA, and OEA quantified by LC-MS. Linear mixed-effects models with participant ID nested in sequence as random effect, including sex as a variable.
Who was studied
N=70 healthy adults, occasional cannabis users, both sexes, Canada.
What this study cannot tell us
Occasional cannabis users—results may differ in naive or chronic users. Plasma levels of endocannabinoids may not reflect brain or tissue levels. The study measured acute effects; chronic CBD use might produce different patterns. Marketed CBD products vary in actual content, so the controlled doses here may not match real-world products. The 2026 publication date means this is very recent and awaits replication.
How to read the evidence
Triple-blind, placebo-controlled, randomized crossover trial with 70 participants—one of the most rigorous CBD pharmacology studies to date.
When this study was published
Published in 2026, representing cutting-edge endocannabinoid pharmacology.
The bigger picture
The sex difference finding parallels RTHC-00155's discovery that cannabis + alcohol impaired memory in men but not women. RTHC-00220 showed that 86% of cannabis users have atypical metabolizing enzyme variants—this study adds biological sex as another source of variability. Together, they paint a picture of cannabis response that's far more individual than the product labels suggest. The anandamide modulation also connects to RTHC-00005's foundational discovery of anandamide itself.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Do the sex differences in endocannabinoid response translate to different clinical outcomes? Should CBD products be dosed differently for men and women? Does chronic CBD use produce sustained changes in endocannabinoid tone?
Read the original research
Sex-specific association between low oral doses of cannabidiol (CBD) and plasma concentration of anandamide (AEA), N-palmitoylethanolamine (PEA) and N-oleoylethanolamine (OEA) in healthy occasional cannabis users.
Journal of cannabis research, 8(1), 20
The Journal of Cannabis Research is a peer-reviewed journal focusing on cannabis science and its applications.
Citation
Abboud, Anita; Chester, Lucy Ann; Hébert, Francois-Olivier; Jutras-Aswad, Didier. (2026). Sex-specific association between low oral doses of cannabidiol (CBD) and plasma concentration of anandamide (AEA), N-palmitoylethanolamine (PEA) and N-oleoylethanolamine (OEA) in healthy occasional cannabis users.. Journal of cannabis research, 8(1), 20. https://doi.org/10.1186/s42238-025-00356-x
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk